AbClon announced on the 31st that it will present the latest research findings on its immuno-oncology drug candidate AM105 at the American Association for Cancer Research (AACR) Annual Meeting 2025.

AACR, the world's largest cancer research conference, will be held in Chicago, USA, from April 25th to 30th. Experts from the global pharmaceutical and biotech industries will gather to present research results and explore global collaborations.

The bispecific antibody therapy AM105 is composed of a novel monoclonal antibody based on AffiMab technology and Affibody. It is a next-generation immuno-oncology antibody platform that effectively eliminates cancer cells by simultaneously targeting EGFR, a major tumor target in colorectal and lung cancer, and CD137, the co-stimulatory factors of T-cell.

AbClon will present differentiated mechanisms of action and animal study results based on the superior efficacy of AM105. In particular, the company plans to demonstrate the potential of its bispecific antibody platform AffiMab to overcome resistance, focusing on its superior anti-cancer effects compared to existing EGFR-targeted therapies. This is expected to provide new treatment options for patients whose response to existing therapies has diminished due to resistance.

Furthermore, AM105 demonstrates potential anti-cancer effects not only in patients with limited response to representative antibody therapies such as Cetuximab and Panitumumab, but also in patients with resistance to EGFR inhibitors such as Gefitinib and Erolotinib. The company explained that this differentiated mechanism of action suggests the potential for AM105 to expand into various cancer types, including colorectal and lung cancer, and is attracting attention as an innovative approach to overcoming EGFR resistance.

An AbClon representative stated, "We will pursue collaboration with global pharmaceutical companies and explore various collaboration opportunities such as technology transfer and joint development. We will strive to widely publicize the potential of AM105 as a next-generation therapy for colorectal and lung cancer, and to provide new hope for patients with intractable cancers who lack treatment options due to EGFR resistance."

Lung cancer is the most common cancer worldwide, with approximately 2.5 million new cases occurring annually, accounting for 12.4% of all cancers. Colorectal cancer also has 1.9 million new cases annually, accounting for 9.6% of all new cancer cases. The lung cancer treatment market is projected to reach $56 billion by 2030, and the colorectal cancer treatment market is expected to reach $18.1 billion.